Literature DB >> 24815307

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.

Ahmet Emre Eskazan1, Mesut Ayer, Bulent Kantarcioglu, Deniz Arica, Naciye Demirel, Demet Aydin, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal.   

Abstract

Entities:  

Keywords:  chronic myeloid leukaemia; efficacy; generic; imatinib mesylate

Mesh：

Substances：

Year:  2014        PMID： 24815307     DOI： 10.1111/bjh.12937

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Authors:  Ahmet Emre Eskazan; Teoman Soysal
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

2.  Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Authors:  Adi J Klil-Drori; Hui Yin; Laurent Azoulay; Michaël Harnois; Michel-Olivier Gratton; Lambert Busque; Sarit E Assouline
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

3.  Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.

Authors:  Ashley M Perry; Andrew M Brunner; Tao Zou; Kristin L McGregor; Philip C Amrein; Gabriela S Hobbs; Karen K Ballen; Donna S Neuberg; Amir T Fathi
Journal:  Cancer       Date:  2017-05-02       Impact factor: 6.860

4.  Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.

Authors:  Maria Gemelli; Elena Maria Elli; Chiara Elena; Alessandra Iurlo; Tamara Intermesoli; Margherita Maffioli; Ester Pungolino; Maria Cristina Carraro; Mariella D'Adda; Francesca Lunghi; Michela Anghileri; Nicola Polverelli; Marianna Rossi; Mattia Bacciocchi; Elisa Bono; Cristina Bucelli; Francesco Passamonti; Laura Antolini; Carlo Gambacorti-Passerini
Journal:  Blood Res       Date:  2020-09-30

5.  Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Authors:  Iman Abou Dalle; Hagop Kantarjian; Jan Burger; Zeev Estrov; Maro Ohanian; Srdan Verstovsek; Farhad Ravandi; Gautam Borthakur; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Journal:  Cancer Med       Date:  2019-09-10       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.